Immunogenicity and Protective Efficacy of a Polyvalent DNA Vaccine against Human Orthopoxvirus Infections Based on Smallpox Virus Genes

Table 1

Primers used to amplify VARV genes by PCR.

VARV gene	Primer sequence	Amplicon size (bp)	DNA vaccine
A30L	5′-CCCGG CTAGC CGCCACC ATGGACGGAACTCTTTTCCCTG-3′	360	pBKRSV-A30L
	5′-CCCGT CGACGTTACTCATATGGGCGCCGAC-3′		pcDNA-A30L
A36R	5′-CCCGGCTAGC CGCCACC ATGATGACACCAGAAAACGAC-3′	581	pBKRSV-A36R
	5′-CCCGT CGAC TTAGTTCATTGTTTTAACACAAAAAT-3′		pcDNA-A36R
B7R	5′-CCCGGCTAGC CGCCACC ATGAAAACGATTTCCGTTGTTA-3′	992	pBKRSV-B7R
	5′-CCCGT CGACACGGATTTATATTCACAGCAACA-3′		pcDNA-B7R
F8L	5′-CCCGGCTAGC CGCCACC ATGTCACAACAACTATCTCCTA-3′	944	pBKRSV-F8L
	5′-CCCGT CGACAATCTAGTTTTGTTTTTCTCG-3′		pcDNA-F8L
M1R	5′-CCCCGCTAGC CGCCACC ATGGGTGCCGCGGCAAG-3′	781	pBKRSV-M1R
	5′-CCCCGTCGACTTCAGTTTTGTATATCCGTGGTAGCAAT-3′		pcDNA-M1R

AsuNHI (GCTAGC) and SalI (GTCGAC) sites for cloning sequence are boldfaced; initiation and stop codons are underlined; a Kozak sequence added between the initiation codon and protein sequence is italicized.